Morphocell Technologies is a regenerative-medicine company pioneering next-generation tissue therapeutics for organ replacement, with a proprietary iPSC platform that supports a pipeline of engineered tissues. Its lead program, ReLiver®, is being advanced toward clinical proof-of-concept to address liver disease. Founded in 2018, the company operates vertically integrated discovery, cell-manufacturing and pre-clinical development facilities from its headquarters in the Greater Montréal Area and offices in Cambridge (Boston) and Toronto. Morphocell has grown to 44 employees and plans to open its first European subsidiary in Italy to access local talent and research infrastructure. Backed by substantial institutional investors, the company now has more than three years of operating runway. Proceeds from its latest financing will expand manufacturing capacity, deepen global collaborations and lay the groundwork for future funding rounds.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025